文献速递冠心病心律失常

利伐沙班单药治疗稳定性冠心病合并房颤的年龄分层效果:AFIRE随机临床试验事后分析

Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2025-08-13

该研究为AFIRE随机临床试验的事后分析,纳入2215例房颤合并稳定性冠心病患者,按年龄分层比较利伐沙班单药与联合抗血小板治疗的效果。结果显示,利伐沙班单药在各年龄组均降低主要心血管事件和大出血风险,尤其在80岁以上患者中疗效更显著,但年龄交互作用不显著,需进一步研究验证。

要点

  • 利伐沙班单药在≥80岁患者中主要心血管事件风险显著降低(HR 0.61,95%CI 0.40-0.93)。
  • 利伐沙班单药在<70岁患者中大出血风险显著降低(HR 0.23,95%CI 0.06-0.79)。

核心结论

  • 利伐沙班单药在广泛年龄范围内降低房颤合并稳定性冠心病患者的主要心血管事件和大出血风险。
  • 年龄相关趋势差异(老年疗效更显著、年轻安全性更显著)仅为假设生成,需进一步研究。

研究设计与样本

  • AFIRE开放标签随机临床试验的事后二次分析,日本多中心研究,2015年2月23日至2018年7月31日。
  • 纳入2215例房颤合并稳定性冠心病患者(平均年龄74.3岁,标准差8.2;男性1751例,占79.1%)。
  • 患者按年龄分为<70岁、70-74岁、75-79岁、≥80岁四组。
  • 干预为利伐沙班单药或利伐沙班联合抗血小板药物治疗。

主要发现

  • 主要疗效终点(主要不良心血管事件)每患者年发生率:单药 vs 联合治疗,<70岁为3.2% vs 4.3%,70-74岁为3.2% vs 2.8%,75-79岁为3.8% vs 5.3%,≥80岁为6.2% vs 10.3%。
  • 主要安全终点(大出血)每患者年发生率:单药 vs 联合治疗,<70岁为0.5% vs 2.3%,70-74岁为2.2% vs 2.4%,75-79岁为1.1% vs 2.1%,≥80岁为2.9% vs 4.3%。

临床怎么用

  • 对于房颤合并稳定性冠心病患者,利伐沙班单药可作为抗栓治疗选择,尤其在高龄患者中可能获益更多。
  • 临床决策时应结合患者年龄、出血和缺血风险个体化评估,注意年龄相关趋势的假设生成性质。

局限性

  • 本研究为事后分析,结果需谨慎解读,年龄相关差异仅为假设生成。
  • 开放标签设计可能引入偏倚。
  • 研究仅在日本进行,人群外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Antithrombotic therapy is crucial for older patients with coronary artery disease (CAD) and atrial fibrillation (AF) who are at a high risk of bleeding and thrombotic events. OBJECTIVE: To examine the age-stratified effects of rivaroxaban monotherapy compared with those of rivaroxaban plus antiplatelet agent combination therapy. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc secondary analysis of the Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease (AFIRE) open-label randomized clinical trial. This was a multicenter study conducted in Japan from February 23, 2015, to July 31, 2018. Patients with AF and stable CAD who had undergone percutaneous coronary intervention or coronary artery bypass grafting 1 or more years earlier or who had angiographically confirmed CAD that did not require revascularization were enrolled. Participants were stratified into 4 groups by age (<70 years, 70-74 years, 75-79 years, and ≥80 years). Study data were analyzed from August 2024 to July 2025. INTERVENTIONS: Rivaroxaban monotherapy or rivaroxaban plus antiplatelet agent therapy. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was a major adverse cardiovascular event, defined as a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, or death from any cause. The primary safety end point was major bleeding. RESULTS: This study included a total of 2215 participants (mean [SD] age, 74.3 [8.2] years; 1751 male [79.1%]). The incidence of primary efficacy end points per patient-year for rivaroxaban monotherapy vs rivaroxaban plus antiplatelet agent therapy was 3.2% vs 4.3% (<70 years), 3.2% vs 2.8% (70-74 years), 3.8% vs 5.3% (75-79 years), and 6.2% vs 10.3% (≥80 years). The hazard ratios were 0.74 (95% CI, 0.40-1.37) for those younger than 70 years, 1.16 (95% CI, 0.55-2.45) for those aged 70 to 74 years, 0.72 (95% CI, 0.41-1.26) for those aged 75 to 79 years, and 0.61 (95% CI, 0.40-0.93) for those 80 years and older (P for interaction =.51). For the primary safety end points, the incidence was 0.5% vs 2.3% (<70 years), 2.2% vs 2.4% (70-74 years), 1.1% vs 2.1% (75-79 years), and 2.9% vs 4.3% (≥80 years). The hazard ratios were 0.23 (95% CI, 0.06-0.79) for those younger than 70 years, 0.91 (95% CI, 0.39-2.15) for those aged 70 to 74 years, 0.52 (95% CI, 0.19-1.42) for those aged 75 to 79 years, and 0.67 (95% CI, 0.35-1.27) for those 80 years and older (P for interaction =.33). CONCLUSIONS AND RELEVANCE: Results of this post hoc analysis of the AFIRE randomized clinical trial reveal that rivaroxaban monotherapy reduced the risk of major cardiovascular events and major bleeding across the broad range of age in patients with AF and stable CAD. Possible age-related differences in trends, with more pronounced efficacy in older patients and more pronounced safety in younger patients, should be considered as hypothesis generating and require further research. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02642419.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Yamaguchi J, Arashi H, Hagiwara N, et al. Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40802193. doi:10.1001/jamacardio.2025.2611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。